Clover Health Investments Corp (CLOV) concluded trading on Wednesday at a closing price of $3.46, with 4.6 million shares of worth about $15.93 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -13.50% during that period and on April 23, 2025 the price saw a gain of about 2.37%. Currently the company’s common shares owned by public are about 395.74M shares, out of which, 383.18M shares are available for trading.
Stock saw a price change of -6.99% in past 5 days and over the past one month there was a price change of -9.19%. Year-to-date (YTD), CLOV shares are showing a performance of 9.84% which increased to 444.37% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.61 but also hit the highest price of $4.87 during that period. The average intraday trading volume for Clover Health Investments Corp shares is 5.98 million. The stock is currently trading -2.70% below its 20-day simple moving average (SMA20), while that difference is down -8.99% for SMA50 and it goes to 3.64% higher than SMA200.
Clover Health Investments Corp (NASDAQ: CLOV) currently have 395.74M outstanding shares and institutions hold larger chunk of about 18.26% of that.
The stock has a current market capitalization of $1.77B and its 3Y-monthly beta is at 1.96. It has posted earnings per share of -$0.09 in the same period. It has a debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CLOV, volatility over the week remained 4.74% while standing at 6.23% over the month.
Analysts are in expectations that Clover Health Investments Corp (CLOV) stock would likely to be making an EPS of -0.07 in the current quarter, while forecast for next quarter EPS is 0.0 and it is -0.12 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.07 which is -0.07 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.05 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -80.25% while it is estimated to increase by 37.99% in next year. EPS is likely to grow at an annualized rate of 40.98% for next 5-years, compared to annual growth of -237.67% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Craig Hallum on December 17, 2024 offering a Buy rating for the stock and assigned a target price of $6 to it. Coverage by UBS stated Clover Health Investments Corp (CLOV) stock as a Neutral in their note to investors on October 07, 2024, suggesting a price target of $4 for the stock. On February 02, 2022, Cowen Upgrade their recommendations, while on February 02, 2022, Canaccord Genuity Initiated their ratings for the stock with a price target of $6. Stock get a Mkt perform rating from SVB Leerink on January 19, 2022.
